



Effects of statin medication on mortality risk associated with type 2 diabetes in older persons The population-based AGES-Reykjavik Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000132
Article Type:	Research
Date Submitted by the Author:	18-Apr-2011
Complete List of Authors:	Olafsdottir, Elin; University of Iceland, Center of Public health Sciences Aspelund, Thor; Icelandic Heart Association, Research Institute Sigurdsson, Gunnar; University of Iceland, Medicine Thorsson, Bolli; Icelandic Heart Association, Research Institute Eiriksdottir, Gudny; Icelandic Heart Association, Research Institute Harris, Tamara; National Institute on Aging, Intramural Research Program Launer, Lenore; National Institute on Aging, Intramural Research Program Benediktsson, Rafn; University of Iceland, Medicine Gudnason, Vilmondur; Icelandic Heart Association, Research Institute
Subject Heading:	Epidemiology
Keywords:	EPIDEMIOLOGY, DIABETES & ENDOCRINOLOGY, statins, cardiovascular disease, mortality

SCHOLARONE™
Manuscripts

1
2
3 **Effects of statin medication on mortality risk**
4
5
6 **associated with type 2 diabetes in older persons**
7

8
9 **The population-based AGES-Reykjavik Study**

10 Elin Olafsdottir,^{1,2} Thor Aspelund,^{1,3} Gunnar Sigurdsson,^{3,4} Bolli Thorsson,¹ Gudny
11 Eiriksdottir,¹ Tamara B. Harris,⁵ Lenore L. Launer,⁵ Rafn Benediktsson,^{3,4} Vilmundur
12 Gudnason,^{1,3}
13
14
15
16
17

18
19
20
21 ¹Icelandic Heart Association Research Institute, Kopavogur, Iceland

22
23 ²Center of Public Health Sciences, University of Iceland, Reykjavik, Iceland

24
25 ³Faculty of Medicine, University of Iceland, Reykjavik, Iceland

26
27 ⁴Landspítali University Hospital, Reykjavik, Iceland

28
29 ⁵Intramural Research Program, National Institute on Aging, Bethesda, MD, USA.
30
31
32

33
34 Corresponding author:

35
36 Professor Vilmundur Gudnason

37
38 Icelandic Heart Association Research Institute

39
40 Holtasmari 1

41
42 201 Kopavogur

43
44
45
46 Iceland

47
48 Icelandic Heart Association, telephone (+354) 535 1800, fax (+354) 535 1801

49
50 e-mail: v.gudnason@hjarta.is

51
52 Running title: Statins and mortality in T2D

53
54 Abstract: 258 words. Main text: 2721 words. Three tables and one figure.

55
56 Supplement with two tables and two figures.
57
58
59
60

ABSTRACT

Objective To examine if the beneficial effect of statin medication on mortality seen in randomised clinical trials of type 2 diabetes, applies equally to observational studies in the general population of older people.

Design A prospective, population-based cohort study.

Setting Reykjavik, Iceland.

Participants 5152 men and women from the Age, Gene/Environment Susceptibility - Reykjavik study, mean age 77 years, range of 66-96 years.

Main outcome measure Cardiovascular and all-cause mortality rates and the relative risk of dying according to statin use and history of coronary heart disease (CHD) in persons with type 2 diabetes and those without diabetes with a median follow up time of 5.3 years, until end of 2009.

Results The prevalence of type 2 diabetes was 12.4% of which 35% used statins. Statin use was associated with a 50% (95% confidence interval 8% to 72%) lower cardiovascular mortality and 53% (29% to 68%) lower all-cause mortality rates in persons with diabetes. For those without diabetes, statin use was associated with a 16% (-24% to 43%) lower cardiovascular and 30% (11% to 46%) lower all-cause mortality rates. Persons with diabetes using statins had a comparable risk of cardiovascular and all-cause mortality as the general population without diabetes. The effect was independent of the level of glycemic control.

Conclusion This observational study lends important support to existing data from randomised clinical trials. Our data suggest that in the general population of older people with diabetes, statin medication markedly reduces the excess cardiovascular and all-cause mortality risk, irrespective of the presence or absence of CHD or glucose-lowering medication.

Article focus

- Clinical trials have shown that statin medication is beneficial for persons with diabetes as regards cardiovascular morbidity and mortality.
- This is not well established except within the rigours of randomised clinical studies.

Key message

- This population-based observational study of older individuals demonstrates that treatment with statins in persons with diabetes reduces cardiovascular mortality rate to a level comparable to what is observed in those without diabetes.
- The effect observed is of comparable magnitude to the effect reported in randomised clinical trials.

Strengths and limitations of this study

- A major strength of the study is the proportionally large national representation in this population-based cohort, the high participation rate and the comprehensive information on morbidity and mortality. The effect observed is of comparable magnitude to the effect reported in randomised clinical trials.
- A limitation is the non-attendance of frail individuals in the study that may cause a possible bias. Non-attendees in the study have been shown, however, at earlier visits to have comparable levels of conventional cardiovascular risk factors. A weakness in our study is the relatively low number of events during the five-year follow-up.

1
2
3 **Key words** Cohort study, type 2 diabetes, statins, older persons, cardiovascular disease
4
5 mortality, AGES-Reykjavik
6
7
8
9

10 11 12 **Abbreviations**

13
14
15 AGES-Reykjavik, Age, Gene/Environment Susceptibility - Reykjavik Study; BMI, body
16
17 mass index; BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart
18
19 disease; 95% confidence interval, 95%CI; CRP, C-reactive protein; CVD, cardiovascular
20
21 disease; HbA_{1c}, haemoglobin A_{1c}; ICD-9 and ICD-10, International Statistical
22
23 Classification of Diseases and Related Health Problems 9th and 10th Revision; MI,
24
25 myocardial infarction; PCI, percutaneous transluminal coronary intervention; SD, standard
26
27 deviation; TG, triglycerides; WHO, World Health Organization
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The excess risk of vascular disease in persons with diabetes is about twofold compared with those without diabetes and is independent of other conventional cardiovascular risk factors. This was clearly demonstrated in the meta-analysis from 102 prospective trials, recently published by the Emerging Risk Factors Collaboration¹. The beneficial effects of statins in reducing major vascular events in patients with diabetes, irrespective of their baseline lipid levels, have been demonstrated in a number of randomised clinical trials²⁻⁵. Additionally, improved life expectancy in recent years of persons with type 2 diabetes, relative to those without diabetes, has been reported⁶⁻⁸, although a difference still exists. This improvement is possibly a result of better adherence to published clinical guidelines, advocating aggressive multifactorial treatment⁹. However, many patients with type 2 diabetes are still not receiving treatment with statin medication^{10, 11}

Although randomised clinical trials have clearly demonstrated the benefit of statin use with regard to cardiovascular morbidity and mortality, every physician will daily face the question whether these trial results apply to his patient. A general population of individuals, with a varied background of co-morbidities which may or may not have excluded them from participation, is not fully represented in the aforementioned trials. This is why it is of key importance to gather confirmatory information from population-based observational studies. One recent prospective population-based study¹⁰ from the U.K. General Practice Database has indeed reported the beneficial effect of statin treatment in lowering all-cause mortality in type 2 diabetes. Older persons are under-represented in clinical trial data and it is therefore particularly important to obtain information on the potential improvement in life expectancy with statin use in older persons with type 2 diabetes, as well as data on the relative impact of lipid lowering treatment in that age group. This will help in clarifying at a population-based level whether current guidelines

1
2
3 should be applied to older persons, who may have had diabetes for an extended period of
4
5
6 time.

7
8 The present study addresses this information gap by exploring treatment modalities
9
10 and cardiovascular and total mortality in older individuals with diabetes in the population-
11
12 based Age, Gene/Environment Susceptibility (AGES)-Reykjavik study.
13
14

15 16 17 **METHODS**

18 19 **Study population**

20
21 Between 2002 and 2006 the AGES-Reykjavik study re-examined 5764 unselected
22
23 survivors of the original cohort who had previously participated in the Reykjavik Study¹².
24
25 In the present study 5152 of these survivors are included, with a mean age of 77 years
26
27 (range 66-96) and a median follow up time of 5.3 years. Informed consent was obtained
28
29 from all study participants. The Reykjavik Study cohort originally comprised a random
30
31 sample of 30 795 men and women born in 1907–1935, living in Reykjavik in 1967 that
32
33 were invited to participate in a long-term prospective cardiovascular survey. A total of 19
34
35 381 attended, resulting in 71% recruitment rate¹².
36
37
38
39
40

41 As part of the baseline examination in the AGES-Reykjavik study, a
42
43 comprehensive questionnaire was administered. In order to eliminate any persons with type
44
45 1 diabetes in the study, participants reporting onset of diabetes before the age of 40 were
46
47 not included; neither were participants not completing their questionnaire or having
48
49 incomplete data for other study variables included: 66 had missing data about diabetes
50
51 history on questionnaire; 21 were considered to have diabetes of type 1; 78 had missing
52
53 data on risk factors (cholesterol, systolic blood pressure, body mass index, triglycerides);
54
55 447 had missing HbA1c. Participants were asked to bring all medications and supplements
56
57
58
59
60

1
2
3 used in the previous 2 weeks to the clinic. All participants also had a fasting blood
4
5 specimen drawn and analysed as documented below.
6

7
8 The criteria used for type 2 diabetes diagnosis was either fasting serum glucose of
9
10 ≥ 7 mmol/l at the visit to the clinic, based on the WHO recommendations from 1999¹³, self-
11
12 reported diabetes in the questionnaire and/or use of diabetes medication.
13

14
15 Blood samples were drawn after overnight fasting. Total cholesterol, HDL
16
17 cholesterol, triglycerides, high sensitivity CRP, glucose and HbA1c were analysed on a
18
19 Hitachi 912, using reagents from Roche Diagnostics and following the manufacturer's
20
21 instructions. LDL was calculated using the Friedewald equation¹⁴.
22
23

24
25 Blood pressure was measured with a mercury sphygmomanometer with a large
26
27 cuff, and the mean value of two consecutive blood pressure measurements was used in the
28
29 analysis. Height and weight were measured and BMI calculated as kg/m².
30

31
32 Information on the causes of death was based on data from a complete registry of
33
34 deaths available from the Icelandic National Roster. All-cause mortality was defined
35
36 according to ICD 9-10. In this study we calculated an individual's time at risk from the date
37
38 of participation in the baseline survey until the date of death from cardiovascular disease
39
40 (ICD-9 and ICD-10: defined as in the SCORE project¹⁵) or from all causes, or until the end
41
42 of follow-up in the cohort. The information is collected from National Health System
43
44 Records by the Icelandic Heart Association.
45
46

47
48 The study was approved by the National Bioethics Committee in Iceland (VSN 00-
49
50 063) as well as the Institutional Review Board of the Intramural Research Program of the
51
52 National Institute on Aging and the Data Protection Authority in Iceland.
53
54

55 56 57 **Statistical analyses** 58 59 60

1
2
3 Baseline characteristics of participants by sex and diabetic status in the AGES-Reykjavik
4 study were compared using either linear or logistic regression with age adjustment.
5
6 Skewed variables were log-transformed. The Cox proportional hazards regression model
7
8 was used to estimate mortality rates and hazard ratios for the effect of risk factors and
9
10 statin use. The time on study was used as the time scale. For hazard ratio estimates, an
11
12 adjustment was made for age and sex in a simple model, and additionally for the following
13
14 cardiovascular risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI,
15
16 triglycerides, CRP, hypertensive medication, and current smoking. A separate term was
17
18 used in the survival models to represent subgroups, formed by diabetes, history of CHD
19
20 and statin use. The mortality rate was estimated from the average of the cumulative hazard
21
22 function after a five-year follow-up and represented as the rate per 1000 person-years. The
23
24 proportionality assumption for the hazard ratio associated with type 2 diabetes was
25
26 inspected graphically and by testing the significance of the interaction of type 2 diabetes
27
28 statuses with the logarithm of the follow-up of time analysed as a time-dependent
29
30 covariate. Significance testing was two-sided and based on a 5% probability level. We
31
32 analysed the data using SAS/STAT® software, version 9.2.
33
34
35
36
37
38
39
40
41
42

43 RESULTS

44
45 The mean age of the 5152 AGES-Reykjavik study participants was 77.0 (± 5.8) years, with
46
47 an age range of 66-96 years. The baseline characteristics in men and women with and
48
49 without type 2 diabetes according to statin use are shown in Table 1. A higher percentage
50
51 of individuals with type 2 diabetes were hypertensive than those without diabetes; they
52
53 also had lower HDL-cholesterol but higher triglycerides and BMI, irrespective of statin
54
55 use. Statin medication reduced the mean level of total and LDL-cholesterol similarly in
56
57 those with and without diabetes, or by about 1.2 mmol/l in both men and women. In statin
58
59
60

1
2
3 users CRP was lower by 0.30 mg/l in men and 0.50 mg/l in women without diabetes and
4
5 0.80 and 1.05 mg/l respectively in those with diabetes. The prevalence of coronary heart
6
7 disease estimated from hospital records in persons without diabetes using statins, was
8
9 71.1% in men and 34.4% in women compared to 7.9% and 2.2% respectively in those not
10
11 using statins. In individuals with diabetes the coronary heart disease prevalence was 59.4%
12
13 in men and 24.2% in women using statins, compared to 14.8% and 8.6% respectively in
14
15 those not on statins. Over 93% of all statin users were hypertensive compared to 78% of
16
17 non-statin users.
18
19
20
21

22 The prevalence of type 2 diabetes and use of glucose lowering treatment in men
23
24 and women is shown in Table 2. About 16% of men and 9.5% of women in the cohort had
25
26 type 2 diabetes and the proportion of persons with diabetes undiagnosed at baseline was
27
28 31%. In the group with previously diagnosed type 2 diabetes, 23% of the men and 35% of
29
30 the women controlled their blood sugar level with diet only. As shown in Table 2, less than
31
32 7% of persons with diagnosed diabetes were simultaneously taking 3 or 4 drugs for
33
34 lowering blood glucose. For participants with a prior diagnosis of diabetes, the average
35
36 time from diagnosis at baseline assessment was just over 10 years.
37
38
39
40
41
42

43 **Effect of statins on cardiovascular and all-cause mortality**

44
45 The five-year average cardiovascular disease mortality and all-cause mortality rates for
46
47 those with and without diabetes are shown in Figure 1. Mortality rate is estimated
48
49 according to statin use and prevalence of coronary heart disease, adjusted to age 75, sex
50
51 and the mean levels of cardiovascular risk factors (cholesterol, HDL-cholesterol, systolic
52
53 blood pressure, BMI, triglycerides, hypertensive medication and current smoking) within
54
55 each cohort. About 26% of men and 16% of women without diabetes and about 35% in
56
57 both sexes with diabetes were statin users. Statin medication was administered to 69.2% of
58
59
60

1
2
3 persons with prevalent coronary heart disease and known diabetes compared to 31.6% of
4 those with known diabetes but without coronary heart disease (Supplement Table 1).
5
6

7
8 For individuals with diabetes and prevalent coronary heart disease, statin use was
9 associated with a significantly lower rate of cardiovascular disease mortality (Figure 1a)
10 compared to those not using statins, or 11.3 vs. 24.6 per 1000 person years. This amounts
11 to 54% (95% confidence interval 14% to 75%) lower mortality rate in statin users.
12
13 Similarly statin use was associated with an all-cause mortality rate of 27.8 vs. 63.3 per
14 1000 person years when comparing the same two groups (Figure 1b), amounting to 55%
15 (31% to 71%) lower mortality rate in statin users. In individuals with diabetes but without
16 coronary heart disease, the rate was 48% (1% to 73%) lower for cardiovascular disease
17 mortality and 52% (26% to 69%) lower for all-cause mortality in the group using statins
18 compared to non-statin users. Combining the groups the hazard of cardiovascular disease
19 mortality was 50% lower in statin users compared to non-statin users and all-cause
20 mortality was 53% lower (Supplement Table 2).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Statin use was associated with 16% (-24% to 43%) lower mortality rate in
37 individuals without diabetes as shown in Figure 1, albeit not statistically significant. For
38 all-cause mortality statin users had 30% (11% to 46%) lower mortality rate than in non-
39 statin users.
40
41
42
43
44

45 The effect of statins was not modified by the level of HbA1c, the use of oral
46 hypoglycaemic or hypertensive medication, or whether the diabetes was prevalent or newly
47 diagnosed (Supplement Figures 1 and 2).
48
49
50
51
52

53 The dramatic effect of statin medication use on mortality rate in persons with
54 diabetes is also reflected in the hazard ratios for the relative risk of cardiovascular and all-
55 cause mortality in individuals with diabetes compared to those without as shown in Table
56 3. In persons with diabetes and prevalent coronary heart disease not on statins, the relative
57
58
59
60

1
2
3 risk of dying from cardiovascular disease was 3.33 (2.05 to 5.50) when compared to those
4
5 without diabetes, after adjusting for age, sex and cardiovascular risk factors. The
6
7 individuals treated with statins, however, had a relative risk of 1.51 (0.83 to 2.75). In
8
9 persons with diabetes but without coronary heart disease not on statins, the relative risk
10
11 was 1.40 (1.03 to 1.89) compared to 0.71 (0.31 to 1.62) for those on statins. Adding CRP
12
13 to the risk factor adjustment showed minimal attenuation of the hazard ratios (Table 3).
14
15 This implies that the protective effect of statins is not solely attributable to the effect on
16
17 these cardiovascular risk factors.
18
19
20
21
22
23

24 **DISCUSSION**

25
26 The major finding in our population-based AGES-Reykjavik study of older individuals
27
28 with diabetes is the marked improvement in survival associated with statin medication
29
30 when compared to those not receiving statins, both with respect to cardiovascular and all-
31
32 cause mortality. This is independent of prevalent coronary heart disease or glucose-
33
34 lowering treatment, reducing the mortality rate in individuals with diabetes to a level
35
36 comparable to those without diabetes.
37
38
39
40

41 Statin medication in diabetes has increased gradually during the last decade. Data
42
43 from the U.K. General Practice Research Database showed an increase in statin use from
44
45 about 5% in 1996 to 63.5% in women and 71.0% in men in 2005¹⁰, which was associated
46
47 with hazard ratios of mortality of 0.29 in women and 0.34 in men in the first two years
48
49 following diagnosis of diabetes. Similarly, in Denmark, only 7% of patients receiving
50
51 glucose-lowering medication also received statins in 1997, but this had increased to 62% in
52
53 2007¹¹; information on mortality in that study is however lacking. In our cohort of older
54
55 persons with diabetes the prevalence of statin medication use was 35% overall. In those
56
57 with known diabetes but without coronary heart disease the prevalence of statin medication
58
59
60

1
2
3 use was 31.6%, but 11.6% in the newly diagnosed without coronary heart disease. One
4
5 may speculate if this low prevalence of statin use is due to Icelandic physicians'
6
7
8 unawareness of results from recent clinical trials or simply their belief that the evidence
9
10 does not apply to older patients in general.
11

12
13 It is of course well recognised that statin treatment favourably impacts vascular
14
15 event rates in both those with and without diabetes. In the Heart Protection Study² for
16
17 example it was concluded that 40 mg of simvastatin daily would probably reduce the rate
18
19 of first major vascular event by about a third. Similarly a two-year treatment period with
20
21 atorvastatin in type 2 diabetes in the CARDS study reduced the death rate by 27%,
22
23 prompting an early termination of the trial¹⁶. The authors concluded that lipid-lowering
24
25 treatment should at least receive the same attention as glycemic and blood pressure control
26
27 in type 2 diabetes patients without a history of cardiovascular disease, which is in harmony
28
29 with current clinical guidelines. Aggressive multifactorial treatment of high-risk
30
31 individuals with type 2 diabetes has been shown to be important⁹, and may also be
32
33 appropriate for persons diagnosed above the age of 70. Recent results from several large
34
35 studies^{17, 18} have, however, indicated that caution may be needed as regards aggressive
36
37 glucose lowering treatment in those with long-established coronary heart disease and
38
39 diabetes of long duration. In our study, statin use at baseline, but not use of glucose-
40
41 lowering medication, is associated with the marked reduction of cardiovascular and total
42
43 mortality rate, reducing mortality in those with diabetes to a level similar to those without
44
45 diabetes.
46
47
48
49
50
51

52
53 Statin medication under the rigors of controlled study conditions in selected
54
55 individuals has thus been shown to be helpful^{2, 4 5}. The novelty of our study is that statin
56
57 medication also is very likely to be important in older persons in the community, persons
58
59
60

1
2
3 which may or may not fit the stringent criteria of normality imposed for inclusion into
4
5
6 randomised clinical trials.

7
8 Recently a large meta-analysis¹ demonstrated that the increased cardiovascular
9
10 mortality seen in type 2 diabetes is not explained by conventional cardiovascular risk
11
12 factors. This suggests that the effect of the statins on cardiovascular mortality seen in our
13
14 population-based cohort may reach beyond the statins' effect on cholesterol levels, possibly
15
16 by reducing the damaging effect of inflammatory agents^{19,20}. Inflammation as measured by
17
18 CRP, however, does not appear to be the explanation in our study, as adjusting for CRP in
19
20 the risk models did not attenuate the relative risk although those on statins had markedly
21
22 lower CRP. This warrants further study.
23
24
25
26

27 The prevalence of diabetes in Iceland is changing in the same fashion as in other
28
29 western societies²¹. Furthermore, the Icelandic population is similar to other western
30
31 populations with respect to cardiovascular morbidity and mortality²², and our results are
32
33 therefore applicable to other Caucasian populations. Thus, considerable additional benefit
34
35 can be expected by adhering to the current guidelines on statin use in treating individuals
36
37 with diabetes, also in the older age-groups.
38
39
40

41 In summary, we have estimated the risk of death from cardiovascular disease and
42
43 from all causes in a population-based cohort of older persons with type 2 diabetes. The
44
45 main finding is that statin use, irrespective of glucose-lowering and antihypertensive
46
47 medication, eliminates the difference in the mortality rate of older persons with type 2
48
49 diabetes, compared to those without diabetes. Our study suggests that treatment with
50
51 statins is paramount in the multifaceted management of type 2 diabetes. Strict adherence to
52
53 the current guidelines is therefore of key importance for older persons with diabetes,
54
55 regardless of the presence or absence of cardiovascular disease or the level of glucose or
56
57 blood pressure control.
58
59
60

1
2
3 Our results urgently call for other population-based studies with comparable
4 information to confirm the effect of statin use on mortality in individuals with type 2
5 diabetes.
6
7
8
9

10 11 12 13 14 15 **Acknowledgements**

16
17 This study has been funded by NIH contract N01-AG-1-2100, the NIA Intramural
18 Research Program, Hjartavernd (the Icelandic Heart Association), and Althingi (the
19 Icelandic Parliament). The study is approved by the Icelandic National Bioethics
20 Committee, VSN: 00-063. The researchers are indebted to the participants for their
21 willingness to participate in the study.
22
23
24
25
26
27
28
29
30
31
32
33

34 **Author Contributions:** Dr Gudnason had access to all the data and takes full
35 responsibility for the content of this paper. Drafting of the manuscript: Olafsdottir,
36 Aspelund, Benediktsson and Gudnason. Statistical analysis: Olafsdottir and Aspelund.
37 Data collection and preparation: Olafsdottir, Aspelund, Gudnason, Thorsson, Eiriksdottir,
38 Sigurdsson, Launer and Harris. All authors contributed to the interpretation of the results,
39 read and commented on the manuscript and approved the final version.
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **Conflict of interest statement**

54
55 Dr Gudnason has funding from National Institutes of Health, Icelandic Heart Association,
56 Icelandic Research Council and the European Union. No conflicts of interest were declared
57 by any other authors.
58
59
60

Funding source's role

The Study's sponsors played no role in the study design, the collection, analysis, and interpretation of data or writing of the report. Dr Gudnason had full access to all the data and had final responsibility for submitting the report for publication.

REFERENCES

1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010 Jun 26;375(9733):2215-22.
2. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet*. 2003 Jun 14;361(9374):2005-16.
3. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. *Diabetes Care*. 2006 Jun;29(6):1220-6.
4. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008 Jan 12;371(9607):117-25.
5. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with

- 1
2
3 cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*.
4
5 2009;338:b2376.
6
7
8 6. Gulliford MC, Charlton J. Is relative mortality of type 2 diabetes mellitus
9
10 decreasing? *Am J Epidemiol*. 2009 Feb 15;169(4):455-61.
11
12
13 7. Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Secular decline in mortality
14
15 from coronary heart disease in adults with diabetes mellitus: cohort study. *BMJ*.
16
17 2008;337:a236.
18
19
20 8. Barnett KN, McMurdo ME, Ogston SA, Morris AD, Evans JM. Mortality in people
21
22 diagnosed with type 2 diabetes at an older age: a systematic review. *Age Ageing*. 2006
23
24 Sep;35(5):463-8.
25
26
27 9. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial
28
29 intervention on mortality in type 2 diabetes. *N Engl J Med*. 2008 Feb 7;358(6):580-91.
30
31
32 10. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in
33
34 men and women with type 2 diabetes: a population-based cohort study. *Diabetes Care*.
35
36 2008 Sep;31(9):1761-6.
37
38
39 11. Dominguez H, Schramm TK, Norgaard ML, Abildstrom SZ, Kober L, Jorgensen C,
40
41 et al. Initiation and persistence to statin treatment in patients with diabetes receiving
42
43 glucose-lowering medications 1997- 2006. *Open Cardiovasc Med J*. 2009;3:152-9.
44
45
46 12. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et
47
48 al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied
49
50 phenomics. *Am J Epidemiol*. 2007 May 1;165(9):1076-87.
51
52
53 13. World Health Organization. Expert Committee Definition dacadmaic. Report of a
54
55 WHO consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva; 1999
56
57 1999.
58
59
60

- 1
2
3 14. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density
4 lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on
5 the basis of nationally recommended cutpoints. *Clin Chem*. 1990 Jan;36(1):15-9.
6
7
8
9
10 15. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.
11 Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
12 *Eur Heart J*. 2003 Jun;24(11):987-1003.
13
14
15
16
17 16. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone
18 SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes
19 in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised
20 placebo-controlled trial. *Lancet*. 2004 Aug 21-27;364(9435):685-96.
21
22
23
24
25
26
27 17. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al.
28 Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008 Jun
29 12;358(24):2545-59.
30
31
32
33
34 18. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al.
35 Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J*
36 *Med*. 2009 Jan 8;360(2):129-39.
37
38
39
40
41 19. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al. Reduction
42 in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-
43 Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). *Diabetes Care*.
44 2005 May;28(5):1151-7.
45
46
47
48
49
50
51 20. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al.
52 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after
53 initiation of rosuvastatin: a prospective study of the JUPITER trial. *Lancet*. 2009 Apr
54 4;373(9670):1175-82.
55
56
57
58
59
60

- 1
2
3 21. Bergsveinsson J, Aspelund T, Gudnason V, Benediktsson R. [Prevalence of type 2
4 diabetes mellitus in Iceland 1967-2002]. *Laeknabladid*. 2007 May;93(5):397-402.
5
6
7
8 22. Aspelund T, Thorgeirsson G, Sigurdsson G, Gudnason V. Estimation of 10-year
9 risk of fatal cardiovascular disease and coronary heart disease in Iceland with results
10 comparable with those of the Systematic Coronary Risk Evaluation project. *Eur J*
11 *Cardiovasc Prev Rehabil*. 2007 Dec;14(6):761-8.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Baseline characteristics according to statin use in men and women without and with type 2 diabetes (T2D). The AGES-Reykjavik study from 2002-2006.

Variables (mean ± SD, IQR or %)	Men				Women			
	Statins no		Statins yes		Statins no		Statins yes	
	without T2D	with T2D	without T2D	with T2D	without T2D	with T2D	without T2D	with T2D
(number)	(1357)	(230)	(477)	(128)	(2237)	(186)	(442)	(95)
Age in years	77.4 (±5.8)	77.9 (±6.1)	76.0 (±4.8)	75.5 (±4.4)	77.0 (±6.1)	78.7 (±6.0) ***	76.1 (±4.8)	76.3 (±4.5)
Cholesterol mmol/l	5.57 (±0.93)	5.38 (±0.98) **	4.32 (±0.82)	4.14 (±0.84) *	6.19 (±1.05)	5.97 (±1.01) **	4.96 (±0.83)	4.67 (±0.94) **
HDL cholesterol mmol/l	1.46 (±0.40)	1.26 (±0.34) ***	1.40 (±0.37)	1.26 (±0.33) ***	1.75 (±0.45)	1.53 (±0.41) ***	1.70 (±0.40)	1.48 (±0.41) ***
LDL cholesterol mmol/l	3.61 (±0.85)	3.40 (±0.89) **	2.38 (±0.67)	2.21 (±0.68) **	3.90 (±0.98)	3.73 (±0.91) *	2.71 (±0.72)	2.41 (±0.70) ***
TG mmol/l, median (IQR)	0.97 (0.56)	1.33 (0.83) ***	1.01 (0.65)	1.29 (0.98) ***	1.04 (0.63)	1.38 (0.85) ***	1.11 (0.67)	1.57 (0.85) ***
CRP mg/l, median (IQR)	1.90 (2.70)	2.20 (3.53) **	1.60 (2.20)	1.40 (2.10)	2.00 (3.20)	3.15 (5.65) ***	1.50 (2.10)	2.10 (3.30) *
BMI kg/m ²	26.4 (±3.7)	28.3 (±4.2) ***	27.0 (±3.7)	28.4 (±3.7) ***	27.0 (±4.9)	29.0 (±5.5) ***	26.8 (±4.0)	30.2 (±5.1) ***
Systolic BP mm Hg	142.9 (±20.6)	141.1 (±20.7)	144.1 (±20.3)	148.2 (±19.6) ***	142.2 (±21.0)	143.3 (±21.8)	143.3 (±20.2)	143.6 (±19.7)
Diastolic BP mm Hg	77.0 (±9.4)	74.7 (±10.8) **	74.4 (±9.7)	74.6 (±10.3)	72.6 (9.3)	70.5 (±10.5)*	71.6 (±10.2)	69.7 (±8.9)
Hypertension % [†]	73.5	88.7 ***	91.6	95.3	78.9	88.7 **	92.5	95.8
Hypertensive medication %	50.0	75.2 ***	85.5	87.5	58.7	79.6***	84.6	90.5
Glucose lowering medication	-	46.1	-	64.1	-	36.6	-	64.2
CHD prevalence % [‡]	7.9	14.8**	71.1	59.4*	2.2	8.6***	34.4	24.2*
Family history MI %	30.1	39.1 **	45.2	41.4	40.2	51.6 **	56.7	53.7
Sports current %	51.0	43.9	54.3	45.3	47.1	40.9	50.7	36.8*
Smoking %	11.9	12.2	9.0	9.4	12.4	10.2	12.9	9.5
Haemoglobin A1c %	5.54 (±0.33)	6.38 (±0.88) ***	5.58 (±0.32)	6.55 (±0.79) ***	5.61 (±0.33)	6.32 (±0.95) ***	5.64 (±0.34)	6.58 (±0.88) ***
Glucose mmol/l	5.57 (±0.50)	7.95 (±2.09) ***	5.58 (±0.53)	7.92 (±2.19) ***	5.44 (±0.51)	7.60 (±2.00) ***	5.41 (±0.52)	7.97 (±2.38) ***

Significance estimates for age-adjusted comparison between those with and without T2D and not using statins (no) and statin users (yes): *p<.05; **p<.01; *** p<.001.

[†]Hypertensive are those with systolic BP>140 mmHg, diastolic BP>90 mmHG or on hypertensive medication.

[‡]Prevalence from history of MI, PCI, and CABG in hospital records.

Table 2. Prevalence of type 2 diabetes (T2D) and glucose lowering treatment in the AGES-Reykjavik study 2002-2006.

AGES-Reykjavik study	Men	Women	Men and women	% of total T2D
Total T2D at baseline % (n)	16.3 (358)	9.5 (281)	12.4 (639)	100
Diagnosed at study entry % (n)	5.1 (113)	2.8 (84)	3.8 (197)	31
With prevalent T2D at study entry % (n)	11.2 (245)	6.7 (197)	8.6 (442)	69
Mean T2D duration in years (\pm SD)			10.7 (\pm 10.0)	
Glucose lowering treatment in prevalent T2D				
on special diet only % (n)	23.3 (57)	34.5 (68)		
on diabetic medication % (n)	76.7 (188)	65.5 (129)		
<i>thereof using 1 drug % (n)</i>	43.7 (107)	40.1 (79)		
" <i>using 2 drugs % (n)</i>	25.7 (63)	19.8 (39)		
" <i>using 3 drugs % (n)</i>	6.9 (17)	4.6 (9)		
" <i>using 4 drugs % (n)</i>	0.4 (1)	1.0 (2)		

Table 3. Hazard ratios (HR) for the relative risk of cardiovascular disease (CVD) mortality and all cause mortality in people with type 2 diabetes (T2D) compared to all non-diabetics according to prevalent coronary heart disease (chd) and statin use*. The AGES-Reykjavik study from 2002-2006.

	Adjusted for age and sex		Adjusted for age, sex, and †CVD risk factors		Adjusted for age, sex, †CVD risk factors and CRP	
	HR	95% CI	HR	95% CI	HR	95% CI
Death from CVD						
All T2D	1.71	(1.35 to 2.17)	1.48	(1.15 to 1.90)	1.45	(1.13 to 1.86)
According to chd and statin use:						
T2D with chd not on statins	4.71	(2.93 to 7.58)	3.33	(2.02 to 5.50)	3.20	(1.94 to 5.29)
T2D with chd on statins	1.92	(1.08 to 3.43)	1.51	(0.83 to 2.75)	1.55	(0.85 to 2.82)
T2D without chd and not on statins	1.53	(1.14 to 2.05)	1.40	(1.03 to 1.89)	1.34	(0.99 to 1.82)
T2D without chd and on statins	0.83	(0.37 to 1.85)	0.71	(0.31 to 1.62)	0.75	(0.33 to 1.69)
Death from all causes						
All T2D	1.44	(1.22 to 1.69)	1.35	(1.14 to 1.61)	1.32	(1.11 to 1.57)
According to chd and statin use:						
T2D with chd not on statins	3.48	(2.43 to 4.99)	2.88	(1.98 to 4.18)	2.72	(1.87 to 3.95)
T2D with chd on statins	1.61	(1.10 to 2.37)	1.34	(0.90 to 1.99)	1.37	(0.92 to 2.04)
T2D without chd not on statins	1.34	(1.09 to 1.64)	1.34	(1.08 to 1.64)	1.27	(1.03 to 1.57)
T2D without chd on statins	0.77	(0.46 to 1.28)	0.70	(0.42 to 1.17)	0.73	(0.44 to 1.23)


*Individuals on statin medication are identified as on statins, those not on statin medication as not on statins.

†CVD risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive medication, and current smoking.

1
2
3 **Figure 1.** a) Cardiovascular disease (CVD) mortality rate and b) all cause mortality rate
4 per 1000 person years for subjects without type 2 diabetes (not T2D) and with type 2
5 diabetes (T2D) according to statin use and prevalent coronary heart disease (chd). Rates
6 have been adjusted to age 75, sex and the mean levels of cardiovascular risk factors
7 (cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive
8 medication and current smoking) within each cohort. Follow up was through 2009 (a
9 median period of 5.3 years) for the AGES-Reykjavik study. The vertical lines represent the
10 mortality rate of all without diabetes (not T2D, N=4513)
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1

a)



b)




Figure 1. a) Cardiovascular disease (CVD) mortality rate and b) all cause mortality rate per 1000 person years for subjects without type 2 diabetes (not T2D) and with type 2 diabetes (T2D) according to statin use and prevalent coronary heart disease (chd). Rates have been adjusted to age 75, sex and the mean levels of cardiovascular risk factors (cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive medication and current smoking) within each cohort. Follow up was through 2009 (a median period of 5.3 years) for the AGES-Reykjavik study. The vertical lines represent the mortality rate of all without diabetes (not T2D, N=4513)

180x233mm (96 x 96 DPI)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	Not done
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	Separate terms for subgroups in statistical models
		(c) Explain how missing data were addressed	6

		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6
		(e) Describe any sensitivity analyses	Not done
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	6
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 3
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Figure 1
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	All analyses are by subgroups
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
3 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
4 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only



Effects of statin medication on mortality risk associated with type 2 diabetes in older persons The population-based AGES-Reykjavik Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000132.R1
Article Type:	Research
Date Submitted by the Author:	13-May-2011
Complete List of Authors:	Olafsdottir, Elin; University of Iceland, Center of Public health Sciences Aspelund, Thor; Icelandic Heart Association, Research Institute Sigurdsson, Gunnar; University of Iceland, Medicine Thorsson, Bolli; Icelandic Heart Association, Research Institute Eiriksdottir, Gudny; Icelandic Heart Association, Research Institute Harris, Tamara; National Institute on Aging, Intramural Research Program Launer, Lenore; National Institute on Aging, Intramural Research Program Benediktsson, Rafn; University of Iceland, Medicine Gudnason, Vilmondur; Icelandic Heart Association, Research Institute
Subject Heading:	Epidemiology
Keywords:	EPIDEMIOLOGY, DIABETES & ENDOCRINOLOGY, statins, cardiovascular disease, mortality

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**Effects of statin medication on mortality risk
associated with type 2 diabetes in older persons**

The population-based AGES-Reykjavik Study

Elin Olafsdottir,^{1,2} Thor Aspelund,^{1,3} Gunnar Sigurdsson,^{3,4} Bolli Thorsson,¹ Gudny Eiriksdottir,¹ Tamara B. Harris,⁵ Lenore L. Launer,⁵ Rafn Benediktsson,^{3,4} Vilmundur Gudnason,^{1,3}

¹Icelandic Heart Association Research Institute, Kopavogur, Iceland

²Center of Public Health Sciences, University of Iceland, Reykjavik, Iceland

³Faculty of Medicine, University of Iceland, Reykjavik, Iceland

⁴Landspítali University Hospital, Reykjavik, Iceland

⁵Intramural Research Program, National Institute on Aging, Bethesda, MD, USA.

Corresponding author:

Professor Vilmundur Gudnason

Icelandic Heart Association Research Institute

Holtasmari 1

201 Kopavogur

Iceland

Icelandic Heart Association, telephone (+354) 535 1800, fax (+354) 535 1801

e-mail: v.gudnason@hjarta.is

Running title: Statins and mortality in T2D

Abstract: 258 words. Main text: 2721 words. Three tables and one figure.

Supplement with two tables and two figures.

ABSTRACT

Objective To examine if the beneficial effect of statin medication on mortality seen in randomised clinical trials of type 2 diabetes, applies equally to observational studies in the general population of older people.

Design A prospective, population-based cohort study.

Setting Reykjavik, Iceland.

Participants 5152 men and women from the Age, Gene/Environment Susceptibility - Reykjavik study, mean age 77 years, range of 66-96 years.

Main outcome measure Cardiovascular and all-cause mortality rates and the relative risk of dying according to statin use and history of coronary heart disease (CHD) in persons with type 2 diabetes and those without diabetes with a median follow up time of 5.3 years, until end of 2009.

Results The prevalence of type 2 diabetes was 12.4% of which 35% used statins. Statin use was associated with a 50% (95% confidence interval 8% to 72%) lower cardiovascular mortality and 53% (29% to 68%) lower all-cause mortality rates in persons with diabetes. For those without diabetes, statin use was associated with a 16% (-24% to 43%) lower cardiovascular and 30% (11% to 46%) lower all-cause mortality rates. Persons with diabetes using statins had a comparable risk of cardiovascular and all-cause mortality as the general population without diabetes. The effect was independent of the level of glycaemic control.

Conclusion This observational study lends important support to existing data from randomised clinical trials. Our data suggest that in the general population of older people with diabetes, statin medication markedly reduces the excess cardiovascular and all-cause mortality risk, irrespective of the presence or absence of CHD or glucose-lowering medication.

Article focus

- Clinical trials have shown that statin medication is beneficial for persons with diabetes as regards cardiovascular morbidity and mortality.
- This is not well established except within the rigours of randomised clinical studies.

Key message

- This population-based observational study of older individuals demonstrates that treatment with statins in persons with diabetes reduces cardiovascular mortality rate to a level comparable to what is observed in those without diabetes.
- The effect observed is of comparable magnitude to the effect reported in randomised clinical trials.

Strengths and limitations of this study

- A major strength of the study is the proportionally large national representation in this population-based cohort, the high participation rate and the comprehensive information on morbidity and mortality. The effect observed is of comparable magnitude to the effect reported in randomised clinical trials.
- A limitation is the non-attendance of frail individuals in the study that may cause a possible bias towards more healthy individuals at baseline of this study. Non-attendees in the study have been shown, however, at earlier visits to have comparable levels of conventional cardiovascular risk factors. A limitation is the unavailability of dietary information for this analysis. A weakness in our study is the relatively low number of events during the five-year follow-up. A limitation is the lack of glucose tolerance test for diagnosis of diabetes.

1
2 **Key words** Cohort study, type 2 diabetes, statins, older persons, cardiovascular disease
3
4 mortality, AGES-Reykjavik
5
6
7
8
9

10 **Abbreviations**

11 AGES-Reykjavik, Age, Gene/Environment Susceptibility - Reykjavik Study; BMI, body
12 mass index; BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart
13 disease; 95% confidence interval, 95%CI; CRP, C-reactive protein; CVD, cardiovascular
14 disease; HbA_{1c}, haemoglobin A_{1c}; ICD-9 and ICD-10, International Statistical
15 Classification of Diseases and Related Health Problems 9th and 10th Revision; MI,
16 myocardial infarction; PCI, percutaneous transluminal coronary intervention; SD, standard
17 deviation; TG, triglycerides; WHO, World Health Organization
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The excess risk of vascular disease in persons with diabetes is about twofold compared with those without diabetes and is independent of other conventional cardiovascular risk factors. This was clearly demonstrated in the meta-analysis from 102 prospective trials, recently published by the Emerging Risk Factors Collaboration¹. The beneficial effects of statins in reducing major vascular events in patients with diabetes, irrespective of their baseline lipid levels, have been demonstrated in a number of randomised clinical trials²⁻⁵. Additionally, improved life expectancy in recent years of persons with type 2 diabetes, relative to those without diabetes, has been reported⁶⁻⁸, although a difference still exists. This improvement is possibly a result of better adherence to published clinical guidelines, advocating aggressive multifactorial treatment⁹. However, many patients with type 2 diabetes are still not receiving treatment with statin medication^{10, 11}

Although randomised clinical trials have clearly demonstrated the benefit of statin use with regard to cardiovascular morbidity and mortality, every physician will daily face the question whether these trial results apply to his patient. A general population of individuals, with a varied background of co-morbidities which may or may not have excluded them from participation, is not fully represented in the aforementioned trials. This is why it is of key importance to gather confirmatory information from population-based observational studies. One recent prospective population-based study¹⁰ from the U.K. General Practice Database has indeed reported the beneficial effect of statin treatment in lowering all-cause mortality in type 2 diabetes. Older persons are under-represented in clinical trial data and it is therefore particularly important to obtain information on the potential improvement in life expectancy with statin use in older persons with type 2 diabetes, as well as data on the relative impact of lipid lowering treatment in that age group. This will help in clarifying at a population-based level whether current guidelines

1
2 should be applied to older persons, who may have had diabetes for an extended period of
3
4 time.

5
6 The present study addresses this information gap by exploring treatment modalities
7
8 and cardiovascular and total mortality in older individuals with diabetes in the population-
9
10 based Age, Gene/Environment Susceptibility (AGES)-Reykjavik study.
11

12 13 14 **METHODS**

15 16 **Study population**

17
18 Between 2002 and 2006 the AGES-Reykjavik study re-examined 5764 unselected
19
20 survivors of the original cohort who had previously participated in the Reykjavik Study¹².

21
22 In the present study 5152 of these survivors are included, with a mean age of 77 years
23
24 (range 66-96) and a median follow up time of 5.3 years until end of 2009. Informed
25
26 consent was obtained from all study participants. The Reykjavik Study cohort originally
27
28 comprised a random sample of 30 795 men and women born in 1907–1935, living in
29
30 Reykjavik in 1967 that were invited to participate in a long-term prospective
31
32 cardiovascular survey. A total of 19 381 attended, resulting in 71% recruitment rate¹².

33
34 As part of the baseline examination in the AGES-Reykjavik study, a
35
36 comprehensive questionnaire was administered. In order to eliminate any persons with type
37
38 1 diabetes in the study, participants reporting onset of diabetes before the age of 40 were
39
40 not included; neither were participants not completing their questionnaire or having
41
42 incomplete data for other study variables included: 66 had missing data about diabetes
43
44 history on questionnaire; 21 were considered to have diabetes of type 1; 78 had missing
45
46 data on risk factors (cholesterol, systolic blood pressure, body mass index, triglycerides);
47
48 447 had missing HbA1c. Participants were asked to bring all medications and supplements
49
50
51
52
53
54
55
56
57
58
59
60

1
2 used in the previous 2 weeks to the clinic. All participants also had a fasting blood
3
4 specimen drawn and analysed as documented below.

5
6 The criteria used for type 2 diabetes diagnosis was either fasting serum glucose of
7
8 ≥ 7 mmol/l at the visit to the clinic, based on the WHO recommendations from 1999¹³, self-
9
10 reported diabetes in the questionnaire and/or use of diabetes medication.

11
12 Blood samples were drawn after overnight fasting. Total cholesterol, HDL
13
14 cholesterol, triglycerides, high sensitivity CRP, glucose and HbA1c were analysed on a
15
16 Hitachi 912, using reagents from Roche Diagnostics and following the manufacturer's
17
18 instructions. LDL was calculated using the Friedewald equation¹⁴.

19
20 Blood pressure was measured with a mercury sphygmomanometer with a large
21
22 cuff, and the mean value of two consecutive blood pressure measurements was used in the
23
24 analysis. Height and weight were measured and BMI calculated as kg/m².

25
26 Participants answered questions about frequency of moderate or vigorous physical
27
28 activity, both current and in midlife. Answers were categorized into never, rarely,
29
30 occasionally, moderate or high frequency of participation. In this study a binary variable
31
32 for physical activity was used as an indicator for occasional or higher frequency of
33
34 participation versus never or rarely participating.

35
36 Answers about education were categorized into a binary variable: higher than
37
38 secondary education versus secondary education or less.

39
40 Information on the causes of death was based on data from a complete adjudicated
41
42 registry of deaths available from the Icelandic National Roster
43
44 (<http://www.statice.is/Statistics/Population/Births-and-deaths>). All-cause mortality was defined
45
46 according to ICD 9-10. In this study we calculated an individual's time at risk from the date
47
48 of participation in the baseline survey until the date of death from cardiovascular disease
49
50 (ICD-9 and ICD-10: defined as in the SCORE project¹⁵) or from all causes, or until the end

1
2 of follow-up in the cohort. The information is collected from National Health System
3
4 Records by the Icelandic Heart Association.

5
6 The study was approved by the National Bioethics Committee in Iceland (VSN 00-
7
8 063) as well as the Institutional Review Board of the Intramural Research Program of the
9
10 National Institute on Aging and the Data Protection Authority in Iceland.

11 12 13 14 **Statistical analyses**

15
16 Baseline characteristics of participants by sex and diabetic status in the AGES-Reykjavik
17
18 study were compared using either linear or logistic regression with age adjustment.
19
20 Skewed variables were log-transformed. The Cox proportional hazards regression model
21
22 was used to estimate mortality rates and hazard ratios for the effect of risk factors and
23
24 statin use. The time on study was used as the time scale. For hazard ratio estimates, an
25
26 adjustment was made for age and sex in a simple model, and additionally for the following
27
28 cardiovascular risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI,
29
30 triglycerides, CRP, hypertensive medication, and current smoking. [An additional analysis](#)
31
32 [of mortality rates was done with adjustment for physical activity and education level.](#) A
33
34 separate term was used in the survival models to represent subgroups, formed by diabetes,
35
36 history of CHD and statin use. The mortality rate was estimated from the average of the
37
38 cumulative hazard function after a five-year follow-up and represented as the rate per 1000
39
40 person-years. The proportionality assumption for the hazard ratio associated with type 2
41
42 diabetes was inspected graphically and by testing the significance of the interaction of type
43
44 2 diabetes statuses with the logarithm of the follow-up of time analysed as a time-
45
46 dependent covariate. Significance testing was two-sided and based on a 5% probability
47
48 level. We analysed the data using SAS/STAT® software, version 9.2.

RESULTS

The mean age of the 5152 AGES-Reykjavik study participants was 77.0 (± 5.8) years, with an age range of 66-96 years. The baseline characteristics in men and women with and without type 2 diabetes according to statin use are shown in Table 1. A higher percentage of individuals with type 2 diabetes were hypertensive than those without diabetes; they also had lower HDL-cholesterol but higher triglycerides and BMI, irrespective of statin use. Statin medication reduced the mean level of total and LDL-cholesterol similarly in those with and without diabetes, or by about 1.2 mmol/l in both men and women. In statin users CRP was lower by 0.30 mg/l in men and 0.50 mg/l in women without diabetes and 0.80 and 1.05 mg/l respectively in those with diabetes. The prevalence of coronary heart disease estimated from hospital records in persons without diabetes using statins, was 71.1% in men and 34.4% in women compared to 7.9% and 2.2% respectively in those not using statins. In individuals with diabetes the coronary heart disease prevalence was 59.4% in men and 24.2% in women using statins, compared to 14.8% and 8.6% respectively in those not on statins. Over 93% of all statin users were hypertensive compared to 78% of non-statin users.

The prevalence of type 2 diabetes and use of glucose lowering treatment in men and women is shown in Table 2. About 16% of men and 9.5% of women in the cohort had type 2 diabetes and the proportion of persons with diabetes undiagnosed at baseline was 31%. In the group with previously diagnosed type 2 diabetes, 23% of the men and 35% of the women controlled their blood sugar level with diet only. As shown in Table 2, less than 7% of persons with diagnosed diabetes were simultaneously taking 3 or 4 drugs for lowering blood glucose. For participants with a prior diagnosis of diabetes, the average time from diagnosis at baseline assessment was just over 10 years.

Effect of statins on cardiovascular and all-cause mortality

The five-year average cardiovascular disease mortality and all-cause mortality rates for those with and without diabetes are shown in Figure 1. Mortality rate is estimated according to statin use and prevalence of coronary heart disease, adjusted to age 75, sex and the mean levels of cardiovascular risk factors (cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive medication and current smoking) within each cohort. About 26% of men and 16% of women without diabetes and about 35% in both sexes with diabetes were statin users. Statin medication was administered to 69.2% of persons with prevalent coronary heart disease and known diabetes compared to 31.6% of those with known diabetes but without coronary heart disease (Supplement Table 1).

For individuals with diabetes and prevalent coronary heart disease, statin use was associated with a significantly lower rate of cardiovascular disease mortality (Figure 1a) compared to those not using statins, or 11.3 vs. 24.6 per 1000 person years. This amounts to 54% (95% confidence interval 14% to 75%) lower mortality rate in statin users. Similarly statin use was associated with an all-cause mortality rate of 27.8 vs. 63.3 per 1000 person years when comparing the same two groups (Figure 1b), amounting to 55% (31% to 71%) lower mortality rate in statin users. In individuals with diabetes but without coronary heart disease, the rate was 48% (1% to 73%) lower for cardiovascular disease mortality and 52% (26% to 69%) lower for all-cause mortality in the group using statins compared to non-statin users. Combining the groups the hazard of cardiovascular disease mortality was 50% lower in statin users compared to non-statin users and all-cause mortality was 53% lower (Supplement Table 2).

Statin use was associated with 16% (-24% to 43%) lower cardiovascular mortality rate in individuals without diabetes as shown in Figure 1, albeit not statistically significant.

1
2 For all-cause mortality statin users had 30% (11% to 46%) lower mortality rate than in
3
4 non-statin users.

5
6 The effect of statins was not modified by the level of HbA1c, the use of oral
7
8 hypoglycaemic or hypertensive medication, or whether the diabetes was prevalent or newly
9
10 diagnosed (Supplement Figures 1 and 2).

11 [An additional analysis of mortality rates with adjustment for current physical activity](#)
12 [and education level did not have any material effect on the results or the conclusions](#)
13 [drawn from the data. The additionally adjusted mortality rates are shown in](#)
14 [Supplement Figure 3.](#)

15
16
17
18
19
20 The dramatic effect of statin medication use on mortality rate in persons with
21
22 diabetes is also reflected in the hazard ratios for the relative risk of cardiovascular and all-
23
24 cause mortality in individuals with diabetes compared to those without as shown in Table
25
26 3. In persons with diabetes and prevalent coronary heart disease not on statins, the relative
27
28 risk of dying from cardiovascular disease was 3.33 (2.05 to 5.50) when compared to those
29
30 without diabetes, after adjusting for age, sex and cardiovascular risk factors. The
31
32 individuals treated with statins, however, had a relative risk of 1.51 (0.83 to 2.75). In
33
34 persons with diabetes but without coronary heart disease not on statins, the relative risk
35
36 was 1.40 (1.03 to 1.89) compared to 0.71 (0.31 to 1.62) for those on statins. Adding CRP
37
38 to the risk factor adjustment showed minimal attenuation of the hazard ratios (Table 3).
39
40 This implies that the protective effect of statins is not solely attributable to the effect on
41
42 these cardiovascular risk factors.

43 44 45 **DISCUSSION**

46
47 The major finding in our population-based AGES-Reykjavik study of older individuals
48
49 with diabetes is the marked improvement in survival associated with statin medication

1
2 when compared to those not receiving statins, both with respect to cardiovascular and all-
3
4 cause mortality. This is independent of prevalent coronary heart disease or glucose-
5
6 lowering treatment, reducing the mortality rate in individuals with diabetes to a level
7
8 comparable to those without diabetes.
9

10 Statin medication in diabetes has increased gradually during the last decade. Data
11
12 from the U.K. General Practice Research Database showed an increase in statin use from
13
14 about 5% in 1996 to 63.5% in women and 71.0% in men in 2005¹⁰, which was associated
15
16 with hazard ratios of mortality of 0.29 in women and 0.34 in men in the first two years
17
18 following diagnosis of diabetes. Similarly, in Denmark, only 7% of patients receiving
19
20 glucose-lowering medication also received statins in 1997, but this had increased to 62% in
21
22 2007¹¹; information on mortality in that study is however lacking. In our cohort of older
23
24 persons with diabetes the prevalence of statin medication use was 35% overall. In those
25
26 with known diabetes but without coronary heart disease the prevalence of statin medication
27
28 use was 31.6%, but 11.6% in the newly diagnosed without coronary heart disease. One
29
30 may speculate if this low prevalence of statin use is due to Icelandic physicians'
31
32 unawareness of results from recent clinical trials or simply their belief that the evidence
33
34 does not apply to older patients in general.

35 It is of course well recognised that statin treatment favourably impacts vascular
36
37 event rates in both those with and without diabetes. In the Heart Protection Study² for
38
39 example it was concluded that 40 mg of simvastatin daily would probably reduce the rate
40
41 of first major vascular event by about a third. Similarly a two-year treatment period with
42
43 atorvastatin in type 2 diabetes in the CARDS study reduced the death rate by 27%,
44
45 prompting an early termination of the trial¹⁶. The authors concluded that lipid-lowering
46
47 treatment should at least receive the same attention as glycemic and blood pressure control
48
49 in type 2 diabetes patients without a history of cardiovascular disease, which is in harmony
50
51
52
53
54
55
56
57
58
59
60

1
2 with current clinical guidelines. Aggressive multifactorial treatment of high-risk
3
4 individuals with type 2 diabetes has been shown to be important⁹, and may also be
5
6 appropriate for persons diagnosed above the age of 70. Recent results from several large
7
8 studies^{17, 18} have, however, indicated that caution may be needed as regards aggressive
9
10 glucose lowering treatment in those with long-established coronary heart disease and
11
12 diabetes of long duration. In our study, statin use at baseline, but not use of glucose-
13
14 lowering medication, is associated with the marked reduction of cardiovascular and total
15
16 mortality rate, reducing mortality in those with diabetes to a level similar to those without
17
18 diabetes.

19
20 Statin medication under the rigors of controlled study conditions in selected
21
22 individuals has thus been shown to be helpful^{2, 4 5}. The novelty of our study is that statin
23
24 medication also is very likely to be important in older persons in the community, persons
25
26 which may or may not fit the stringent criteria of normality imposed for inclusion into
27
28 randomised clinical trials.

29
30 Recently a large meta-analysis¹ demonstrated that the increased cardiovascular
31
32 mortality seen in type 2 diabetes is not explained by conventional cardiovascular risk
33
34 factors. This suggests that the effect of the statins on cardiovascular mortality seen in our
35
36 population-based cohort may reach beyond the statins' effect on cholesterol levels, possibly
37
38 by reducing the damaging effect of inflammatory agents^{19, 20}. Inflammation as measured by
39
40 CRP, however, does not appear to be the explanation in our study, as adjusting for CRP in
41
42 the risk models did not attenuate the relative risk although those on statins had markedly
43
44 lower CRP. This warrants further study.

45
46 The prevalence of diabetes in Iceland is changing in the same fashion as in other
47
48 western societies²¹. Furthermore, the Icelandic population is similar to other western
49
50 populations with respect to cardiovascular morbidity and mortality²², and our results are

1
2 therefore applicable to other Caucasian populations. Thus, considerable additional benefit
3
4 can be expected by adhering to the current guidelines on statin use in treating individuals
5
6 with diabetes, also in the older age-groups.
7

8 In summary, we have estimated the risk of death from cardiovascular disease and
9
10 from all causes in a population-based cohort of older persons with type 2 diabetes. The
11
12 main finding is that statin use, irrespective of glucose-lowering and antihypertensive
13
14 medication, eliminates the difference in the mortality rate of older persons with type 2
15
16 diabetes, compared to those without diabetes. Our study suggests that treatment with
17
18 statins is paramount in the multifaceted management of type 2 diabetes. Strict adherence to
19
20 the current guidelines is therefore of key importance for older persons with diabetes,
21
22 regardless of the presence or absence of cardiovascular disease or the level of glucose or
23
24 blood pressure control.

25
26 Our results urgently call for other population-based studies with comparable
27
28 information to confirm the effect of statin use on mortality in individuals with type 2
29
30 diabetes.
31

32 33 34 35 **Acknowledgements**

36
37 This study has been funded by NIH contract N01-AG-1-2100, the NIA Intramural
38
39 Research Program, Hjartavernd (the Icelandic Heart Association), and Althingi (the
40
41 Icelandic Parliament). The study is approved by the Icelandic National Bioethics
42
43 Committee, VSN: 00-063. The researchers are indebted to the participants for their
44
45 willingness to participate in the study.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **Author Contributions:** Dr Gudnason had access to all the data and takes full
3
4 responsibility for the content of this paper. Drafting of the manuscript: Olafsdottir,
5
6 Aspelund, Benediktsson and Gudnason. Statistical analysis: Olafsdottir and Aspelund.
7
8 Data collection and preparation: Olafsdottir, Aspelund, Gudnason, Thorsson, Eiriksdottir,
9
10 Sigurdsson, Launer and Harris. All authors contributed to the interpretation of the results,
11
12 read and commented on the manuscript and approved the final version.
13
14
15
16
17

18 **Conflict of interest statement**

19
20 Dr Gudnason has funding from National Institutes of Health, Icelandic Heart Association,
21
22 Icelandic Research Council and the European Union. No conflicts of interest were declared
23
24 by any other authors.
25
26
27
28
29

30 **Funding source's role**

31
32 The Study's sponsors played no role in the study design, the collection, analysis, and
33
34 interpretation of data or writing of the report. Dr Gudnason had full access to all the data
35
36 and had final responsibility for submitting the report for publication.
37
38
39
40

41 **REFERENCES**

- 42
43 1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al.
44
45 Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a
46
47 collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010 Jun
48
49 26;375(9733):2215-22.
50

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet*. 2003 Jun 14;361(9374):2005-16.
3. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. *Diabetes Care*. 2006 Jun;29(6):1220-6.
4. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008 Jan 12;371(9607):117-25.
5. Brugs JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*. 2009;338:b2376.
6. Gulliford MC, Charlton J. Is relative mortality of type 2 diabetes mellitus decreasing? *Am J Epidemiol*. 2009 Feb 15;169(4):455-61.
7. Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. *BMJ*. 2008;337:a236.
8. Barnett KN, McMurdo ME, Ogston SA, Morris AD, Evans JM. Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. *Age Ageing*. 2006 Sep;35(5):463-8.
9. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med*. 2008 Feb 7;358(6):580-91.

- 1
2 10. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in
3 men and women with type 2 diabetes: a population-based cohort study. *Diabetes Care*.
4 2008 Sep;31(9):1761-6.
5
6
7
- 8 11. Dominguez H, Schramm TK, Norgaard ML, Abildstrom SZ, Kober L, Jorgensen C,
9 et al. Initiation and persistence to statin treatment in patients with diabetes receiving
10 glucose-lowering medications 1997- 2006. *Open Cardiovasc Med J*. 2009;3:152-9.
11
12
- 13 12. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et
14 al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied
15 phenomics. *Am J Epidemiol*. 2007 May 1;165(9):1076-87.
16
17
- 18 13. World Health Organization. Expert Committee Definition dacodmaic. Report of a
19 WHO consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva; 1999
20 1999.
21
22
- 23 14. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density
24 lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on
25 the basis of nationally recommended cutpoints. *Clin Chem*. 1990 Jan;36(1):15-9.
26
27
- 28 15. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.
29 Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
30 *Eur Heart J*. 2003 Jun;24(11):987-1003.
31
32
- 33 16. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone
34 SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes
35 in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised
36 placebo-controlled trial. *Lancet*. 2004 Aug 21-27;364(9435):685-96.
37
38
- 39 17. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al.
40 Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008 Jun
41 12;358(24):2545-59.
42
43
44
45
46
47
48
49
50

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009 Jan 8;360(2):129-39.
19. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). *Diabetes Care*. 2005 May;28(5):1151-7.
20. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. *Lancet*. 2009 Apr 4;373(9670):1175-82.
21. Bergsveinsson J, Aspelund T, Gudnason V, Benediktsson R. [Prevalence of type 2 diabetes mellitus in Iceland 1967-2002]. *Laeknabladid*. 2007 May;93(5):397-402.
22. Aspelund T, Thorgeirsson G, Sigurdsson G, Gudnason V. Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. *Eur J Cardiovasc Prev Rehabil*. 2007 Dec;14(6):761-8.

Table 1. Baseline characteristics according to statin use in men and women without and with type 2 diabetes (T2D). The AGES-Reykjavik study from 2002-2006.

Variables (mean ± SD, IQR or %)	Men		Women		Men		Women	
	Statin no	Statin yes	Statin no	Statin yes	Statin no	Statin yes	Statin no	Statin yes
(number)	(1357)	(230)	(477)	(128)	(2237)	(186)	(442)	(95)
Age in years	77.4 (±5.8)	77.9 (±6.1)	76.0 (±4.8)	75.5 (±4.4)	77.0 (±6.1)	78.7 (±6.0) ***	76.1 (±4.8)	76.3 (±4.5)
Cholesterol mmol/l	5.57 (±0.93)	5.38 (±0.98) **	4.32 (±0.82)	4.14 (±0.84) *	6.19 (±1.05)	5.97 (±1.01) **	4.96 (±0.83)	4.67 (±0.94) **
HDL cholesterol mmol/l	1.46 (±0.40)	1.26 (±0.34) ***	1.40 (±0.37)	1.26 (±0.33) ***	1.75 (±0.45)	1.53 (±0.41) ***	1.70 (±0.40)	1.48 (±0.41) ***
LDL cholesterol mmol/l	3.61 (±0.85)	3.40 (±0.89) **	2.38 (±0.67)	2.21 (±0.68) **	3.90 (±0.98)	3.73 (±0.91) *	2.71 (±0.72)	2.41 (±0.70) ***
TG mmol/l, median (IQR)	0.97 (0.56)	1.33 (0.83) ***	1.01 (0.65)	1.29 (0.98) ***	1.04 (0.63)	1.38 (0.85) ***	1.11 (0.67)	1.57 (0.85) ***
CRP mg/l, median (IQR)	1.90 (2.70)	2.20 (3.53) **	1.60 (2.20)	1.40 (2.10)	2.00 (3.20)	3.15 (5.65) ***	1.50 (2.10)	2.10 (3.30) *
BMI kg/m ²	26.4 (±3.7)	28.3 (±4.2) ***	27.0 (±3.7)	28.4 (±3.7) ***	27.0 (±4.9)	29.0 (±5.5) ***	26.8 (±4.0)	30.2 (±5.1) ***
Systolic BP mm Hg	142.9 (±20.6)	141.1 (±20.7)	144.1 (±20.3)	148.2 (±19.6) ***	142.2 (±21.0)	143.3 (±21.8)	143.3 (±20.2)	143.6 (±19.7)
Diastolic BP mm Hg	77.0 (±9.4)	74.7 (±10.8) **	74.4 (±9.7)	74.6 (±10.3)	72.6 (9.3)	70.5 (±10.5)*	71.6 (±10.2)	69.7 (±8.9)
Hypertension % [†]	73.5	88.7 ***	91.6	95.3	78.9	88.7 **	92.5	95.8
Hypertensive medication %	50.0	75.2 ***	85.5	87.5	58.7	79.6 ***	84.6	90.5
Glucose lowering medication	-	46.1	-	64.1	-	36.6	-	64.2
CHD prevalence % [‡]	7.9	14.8**	71.1	59.4*	2.2	8.6***	34.4	24.2*
Family history MI %	30.1	39.1 **	45.2	41.4	40.2	51.6 **	56.7	53.7
Physical activity in midlife %	51.0	43.9	54.3	45.3	47.1	40.9	50.7	36.8*
Physical activity current %	39.6	27.4***	45.3	35.2*	31.3	26.3	34.2	16.8*
Education, more than secondary%	30.0	27.4	29.8	28.9	21.9	20.4	17.2	16.8
Smoking %	11.9	12.2	9.0	9.4	12.4	10.2	12.9	9.5
Haemoglobin A1c %	5.54 (±0.33)	6.38 (±0.88) ***	5.58 (±0.32)	6.55 (±0.79) ***	5.61 (±0.33)	6.32 (±0.95) ***	5.64 (±0.34)	6.58 (±0.88) ***
Glucose mmol/l	5.57 (±0.50)	7.95 (±2.09) ***	5.58 (±0.53)	7.92 (±2.19) ***	5.44 (±0.51)	7.60 (±2.00) ***	5.41 (±0.52)	7.97 (±2.38) ***

Significance estimates for age-adjusted comparison between those with and without T2D and not using statins (no) and statin users (yes): *p<.05; **p<.01; *** p<.001.

[†]Hypertensive are those with systolic BP>140 mmHg, diastolic BP>90 mmHG or on hypertensive medication.

[‡]Prevalence from history of MI, PCI, and CABG in hospital records.

Formatted: Bottom: 62.9 pt

... [1]

Deleted: ¶

Formatted Table

Formatted Table

Deleted: Sports current

Table 2. Prevalence of type 2 diabetes (T2D) and glucose lowering treatment in the AGES-Reykjavik study 2002-2006.

AGES-Reykjavik study	Men	Women	Men and women	% of total T2D
Total T2D at baseline % (n)	16.3 (358)	9.5 (281)	12.4 (639)	100
Diagnosed at study entry % (n)	5.1 (113)	2.8 (84)	3.8 (197)	31
With prevalent T2D at study entry % (n)	11.2 (245)	6.7 (197)	8.6 (442)	69
Mean T2D duration in years (\pm SD)			10.7 (\pm 10.0)	
Glucose lowering treatment in prevalent T2D				
on special diet only % (n)	23.3 (57)	34.5 (68)		
on diabetic medication % (n)	76.7 (188)	65.5 (129)		
<i>thereof using 1 drug % (n)</i>	<i>43.7 (107)</i>	<i>40.1 (79)</i>		
" <i>using 2 drugs % (n)</i>	<i>25.7 (63)</i>	<i>19.8 (39)</i>		
" <i>using 3 drugs % (n)</i>	<i>6.9 (17)</i>	<i>4.6 (9)</i>		
" <i>using 4 drugs % (n)</i>	<i>0.4 (1)</i>	<i>1.0 (2)</i>		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3. Hazard ratios (HR) for the relative risk of cardiovascular disease (CVD) mortality and all cause mortality in people with type 2 diabetes (T2D) compared to all non-diabetics according to prevalent coronary heart disease (chd) and statin use*. The AGES-Reykjavik study from 2002-2006.

	Adjusted for age and sex		Adjusted for age, sex, and †CVD risk factors		Adjusted for age, sex, †CVD risk factors and CRP	
	HR	95% CI	HR	95% CI	HR	95% CI
Death from CVD						
All T2D	1.71	(1.35 to 2.17)	1.48	(1.15 to 1.90)	1.45	(1.13 to 1.86)
According to chd and statin use:						
T2D with chd not on statins	4.71	(2.93 to 7.58)	3.33	(2.02 to 5.50)	3.20	(1.94 to 5.29)
T2D with chd on statins	1.92	(1.08 to 3.43)	1.51	(0.83 to 2.75)	1.55	(0.85 to 2.82)
T2D without chd and not on statins	1.53	(1.14 to 2.05)	1.40	(1.03 to 1.89)	1.34	(0.99 to 1.82)
T2D without chd and on statins	0.83	(0.37 to 1.85)	0.71	(0.31 to 1.62)	0.75	(0.33 to 1.69)
Death from all causes						
All T2D	1.44	(1.22 to 1.69)	1.35	(1.14 to 1.61)	1.32	(1.11 to 1.57)
According to chd and statin use:						
T2D with chd not on statins	3.48	(2.43 to 4.99)	2.88	(1.98 to 4.18)	2.72	(1.87 to 3.95)
T2D with chd on statins	1.61	(1.10 to 2.37)	1.34	(0.90 to 1.99)	1.37	(0.92 to 2.04)
T2D without chd not on statins	1.34	(1.09 to 1.64)	1.34	(1.08 to 1.64)	1.27	(1.03 to 1.57)
T2D without chd on statins	0.77	(0.46 to 1.28)	0.70	(0.42 to 1.17)	0.73	(0.44 to 1.23)

*Individuals on statin medication are identified as on statins, those not on statin medication as not on statins.

†CVD risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive medication, and current smoking.

1
2 **Figure 1.** a) Cardiovascular disease (CVD) mortality rate and b) all cause mortality rate
3
4 per 1000 person years for subjects without type 2 diabetes (not T2D) and with type 2
5
6 diabetes (T2D) according to statin use and prevalent coronary heart disease (chd). Rates
7
8 have been adjusted to age 75, sex and the mean levels of cardiovascular risk factors
9
10 (cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive
11
12 medication and current smoking) within each cohort. Follow up was through 2009 (a
13
14 median period of 5.3 years) for the AGES-Reykjavik study. The vertical lines represent the
15
16 mortality rate of all without diabetes (not T2D, N=4513)
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	Not done
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	Separate terms for subgroups in statistical models
		(c) Explain how missing data were addressed	6


		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6
		(e) Describe any sensitivity analyses	Not done
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	6
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 3
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Figure 1
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	All analyses are by subgroups
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
3 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
4 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



135x135mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



135x135mm (300 x 300 DPI)

